Peter J Houghton

  • 22962 Citations
  • 80 h-Index
1975 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Peter J Houghton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Heterografts Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Rhabdomyosarcoma Medicine & Life Sciences
Sirolimus Medicine & Life Sciences
Topotecan Medicine & Life Sciences
Vincristine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1975 2019

A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)

Mosse, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D., Barkauskas, D. A., Krailo, M., Voss, S. D., Berg, S. L., Blaney, S. M. & Weigel, B. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3229-3238 10 p.

Research output: Contribution to journalArticle

Open Access
Leukemia
Aurora Kinase A
Neoplasms
Pharmacokinetics
Pharmacogenetics

Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

Lowery, C. D., Dowless, M., Renschler, M., Blosser, W., VanWye, A. B., Stephens, J. R., Iversen, P. W., Lin, A. B., Beckmann, R. P., Krytska, K., Cole, K. A., Maris, J. M., Hawkins, D. S., Rubin, B. P., Kurmasheva, R. T., Houghton, P. J., Gorlick, R., Anders Kolb, E., Kang, M. H., Patrick Reynolds, C. & 4 othersErickson, S. W., Teicher, B. A., Smith, M. A. & Stancato, L. F., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2278-2289 12 p.

Research output: Contribution to journalArticle

Pediatrics
Neoplasms
Combination Drug Therapy
Heterografts
Cell Line

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]

Bailey, K., Cost, C., Davis, I., Glade-Bender, J., Grohar, P., Houghton, P. J., Isakoff, M., Stewart, E., Laack, N., Yustein, J., Reed, D., Janeway, K., Gorlick, R., Lessnick, S., DuBois, S. & Hingorani, P., Jan 1 2019, In : F1000Research. 8, 493.

Research output: Contribution to journalReview article

Open Access
Peer Review
Ewing's Sarcoma
Oncology
Proxy
Advisory Committees

Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models

Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Del Pozo, V., Ghilu, S., Phelps, D. A., Erickson, S. W., Peer, C. J., Figg, W. D., Smith, M. A. & Houghton, P. J., Jan 1 2019, In : Pediatric Blood and Cancer. e27820.

Research output: Contribution to journalArticle

Rhabdomyosarcoma
Cytotoxins
Standard of Care
Heterografts
Pharmacokinetics

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Jones, L., McCalmont, H., Evans, K., Mayoh, C., Kurmasheva, R. T., Billups, C. A., Houghton, P. J., Smith, M. A. & Lock, R. B., Jan 1 2019, In : Pediatric Blood and Cancer. e27765.

Research output: Contribution to journalArticle

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Leukemia
Pediatrics
Antibodies